Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as an oral tablet for oral use. It is prescribed for the short‑term treatment of insomnia in adults who have difficulty falling or staying asleep.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is a sedative‑hypnotic that acts on the central nervous system to manage sleep disorders.

Insomnia (difficulty falling asleep): helps initiate sleep and reduce sleep latency. Insomnia (difficulty staying asleep): decreases nocturnal awakenings and improves sleep continuity. Insomnia (early morning awakening): extends total sleep time and promotes restorative sleep.

Common Side Effects: - Drowsiness or fatigue - Metallic or bitter taste in the mouth - Dry mouth - Headache - Dizziness - Short‑term memory impairment

Serious or Rare Side Effects: - Allergic reactions such as rash, itching or swelling - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Depression or suicidal thoughts - Respiratory depression, especially with other CNS depressants - Abnormal heart rhythm or palpitations - Severe hypotension or syncope

Zopiclone should be used with caution and under medical supervision. - Assess duration of insomnia: limit use to short‑term periods as advised by a prescriber. - Avoid alcohol: concurrent consumption may intensify central nervous system depression. - Monitor elderly patients: increased sensitivity may raise fall risk. - Caution in hepatic impairment: dose adjustment may be required. - Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Zopiclone may interact with other medications that affect the central nervous system.

Major Interactions (Avoid): - Alcohol: additive sedation and respiratory depression. - Opioids: heightened risk of profound CNS depression. - Other sedative‑hypnotics (e.g., benzodiazepines): excessive sedation.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase plasma concentrations. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Antidepressants (e.g., fluoxetine, sertraline): can enhance sedative properties.